Minerva Neurosciences, Inc.

NasdaqCM:NERV Stock Report

Market Cap: US$15.2m

Minerva Neurosciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Remy Luthringer

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage34.0%
CEO tenure10yrs
CEO ownership2.6%
Management average tenure8.6yrs
Board average tenure9.5yrs

Recent management updates

Recent updates

Minerva says FDA declined to accept marketing application for schizophrenia drug

Oct 17

Minerva Neurosciences: Biotech On The Move

Aug 29

Minerva stock rises on filing for FDA approval of schizophrenia therapy

Aug 22

We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Jun 22
We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Jan 26
Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Oct 02
Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Mar 03
Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Jan 27
What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

Dec 23
We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

A Potential Trade Arises On Minerva

Dec 09

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Nov 18
A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Minerva Neurosciences EPS beats by $0.03

Nov 02

CEO Compensation Analysis

How has Remy Luthringer's remuneration changed compared to Minerva Neurosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$3m

Jun 30 2024n/an/a

-US$34m

Mar 31 2024n/an/a

-US$32m

Dec 31 2023US$2mUS$624k

-US$30m

Sep 30 2023n/an/a

-US$28m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$600k

-US$32m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$51m

Dec 31 2021US$1mUS$585k

-US$50m

Sep 30 2021n/an/a

-US$36m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

US$5m

Dec 31 2020US$2mUS$565k

US$2m

Sep 30 2020n/an/a

-US$21m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$69m

Dec 31 2019US$1mUS$543k

-US$72m

Sep 30 2019n/an/a

-US$55m

Jun 30 2019n/an/a

-US$54m

Mar 31 2019n/an/a

-US$54m

Dec 31 2018US$4mUS$525k

-US$50m

Sep 30 2018n/an/a

-US$37m

Jun 30 2018n/an/a

-US$36m

Mar 31 2018n/an/a

-US$33m

Dec 31 2017US$2mUS$445k

-US$32m

Compensation vs Market: Remy's total compensation ($USD1.84M) is above average for companies of similar size in the US market ($USD646.00K).

Compensation vs Earnings: Remy's compensation has increased whilst the company is unprofitable.

CEO

Remy Luthringer (63 yo)

10yrs

Tenure

US$1,835,160

Compensation

Dr. Remy Luthringer, Ph D., serves as a Clinical Advisor to the Medicxi investment team and a Member of the Co-Founding team at Medicxi Ventures (UK) LLP. He has played an active role in several Index Vent...

Leadership Team

NamePositionTenureCompensationOwnership
Remy Luthringer
Executive Chairman & CEO10yrsUS$1.84m2.64%
$ 401.1k
Geoffrey Race
President3.1yrsUS$1.40m0.73%
$ 111.4k
Frederick Ahlholm
Senior VP3.1yrsUS$965.12k0.25%
$ 38.0k
Joseph Reilly
Senior VP & COO10.3yrsUS$1.49mno data
William Boni
Vice President of Investor Relations & Corporate Communications9.3yrsno datano data
Michael Davidson
Chief Medical Officer7.9yrsUS$657.47kno data

8.6yrs

Average Tenure

63yo

Average Age

Experienced Management: NERV's management team is seasoned and experienced (8.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Remy Luthringer
Executive Chairman & CEO10yrsUS$1.84m2.64%
$ 401.1k
G. van Heek
Independent Director10.3yrsUS$120.75k0.036%
$ 5.5k
Hans Hasler
Independent Director6.9yrsUS$127.00k0.018%
$ 2.7k
David Kupfer
Lead Independent Director9yrsUS$125.25k0.34%
$ 51.9k
Fouzia Laghrissi-Thode
Independent Director9.5yrsUS$122.25k0%
$ 0

9.5yrs

Average Tenure

68yo

Average Age

Experienced Board: NERV's board of directors are considered experienced (9.5 years average tenure).